TickerFacts.

BridgeBio Oncology Therapeutics, Inc. (BBOT): Shareholders' Equity

Annual figures by period end, from SEC filings.

$411.10M
As of 2025-12-31
$323.11M
As of 2026-06-30
2023-12-31: -$63.6K2024-12-31: -$178.64M2025-12-31: $411.10M$411.10M
2023-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$411.10Mn/m2026-03-05, Balance as of period end
2024-12-31-$178.64Mn/m2026-03-05, Balance as of period end
2023-12-31-$63.6Kn/a2025-03-11, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
BridgeBio Oncology Therapeutics, Inc. (BBOT)2025-12-31$411.10Mn/m
Biohaven Ltd. (BHVN)2025-12-31$52.07M-87.7%
BGM Group Ltd. (BGM)2025-09-30$391.90M+788.8%
Arcutis Biotherapeutics, Inc. (ARQT)2025-12-31$189.48M+20.3%
Bicara Therapeutics Inc. (BCAX)2025-12-31$401.45M-18.4%
MoonLake Immunotherapeutics (MLTX)2025-12-31$304.48M-31.9%
Enliven Therapeutics, Inc. (ELVN)2025-12-31$459.60M+48.3%
MapLight Therapeutics, Inc. (MPLT)2025-12-31$458.37Mn/m
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31$139.07M+540.0%

Compare BBOT, BHVN, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗